OncoMatch/Clinical Trials/NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Is NCT06568094 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for prostate cancer.

Phase 1/2RecruitingJiangsu HengRui Medicine Co., Ltd.NCT06568094Data as of May 2026

Treatment: HRS-5041 tablets · Abiraterone Acetate tablets（II） · Prednisone Acetate tablets · Docetaxel · HRS-1167 tablets · SHR2554 tablets — The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify